2021
DOI: 10.1016/j.jinorgbio.2021.111446
|View full text |Cite
|
Sign up to set email alerts
|

Design of artificial metalloenzymes for the reduction of nicotinamide cofactors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
11
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 11 publications
(11 citation statements)
references
References 32 publications
0
11
0
Order By: Relevance
“…34 Currently, successful cases have been reported in the range of improving protein stability and folding, 34 altering specificity and binding affinity, 35 implanting novel enzymatic activities, and preparing high-ordered assemblies. 36,37 The de novo design process usually starts with an unknown sequence and backbone structure and finally requires the determination of the protein sequence that will fold into a certain structure with novel functionality (Figure 2D). It highly relies on computational tools such as AlphaFold2, 38 Rosetta, 26 and Protein WISDOM.…”
Section: Overview Of the Basic Principles And Strategies Of Protein D...mentioning
confidence: 99%
“…34 Currently, successful cases have been reported in the range of improving protein stability and folding, 34 altering specificity and binding affinity, 35 implanting novel enzymatic activities, and preparing high-ordered assemblies. 36,37 The de novo design process usually starts with an unknown sequence and backbone structure and finally requires the determination of the protein sequence that will fold into a certain structure with novel functionality (Figure 2D). It highly relies on computational tools such as AlphaFold2, 38 Rosetta, 26 and Protein WISDOM.…”
Section: Overview Of the Basic Principles And Strategies Of Protein D...mentioning
confidence: 99%
“…13,[17][18][19] Computational analysis of the dened complexes can also guide the selection of bioconjugation sites in the case of the covalent binding of the metal complex to the protein. 20,21 In other approaches, molecular docking in combination with QM and MD simulations was used to control the activity and selectivity of ArMs by understanding substrate binding affinity, exibility, and orientation. 22,23 Despite the above examples and the similarity of the approach to computational drug design, where chemical structures are non-covalently incorporated within proteins as strongly binding inhibitors, 24 docking is not routinely used in ArM design.…”
Section: Introductionmentioning
confidence: 99%
“…26 In our group, we developed ArMs for the reduction of nicotinamide cofactors, starting from the wild type alcohol dehydrogenase from Thermoanaerobacter brockii (TbADH WT), by covalently binding rhodium piano stool complexes at the place of the catalytic zinc site. 21,27 In this work, we aim to simplify the ArMs by designing catalysts for supramolecular binding to avoid the need for the covalent modication of the protein. So far, ArMs based on supramolecular anchoring rely on systems where a natural affinity between the protein and ligand is a pre-requisite, thereby limiting the protein and/or ligand choice; whereas systematic rational strategies to specically design the metal catalysts for supramolecular anchoring to a selected protein scaffold are yet to be developed.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Co-immobilized amine and formate dehydrogenases were used in the continuous production of chiral amine in a packed bed reactor (Franklin et al, 2021 ). FDH catalysis served as a model for the development of artificial metalloenzymes reducing nicotinamide cofactors resilient to high temperatures, compatible with solvents, and lacking FDH complexity (Basle et al, 2021 ).…”
Section: Introductionmentioning
confidence: 99%